Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

RAB0210

Sigma-Aldrich

Mouse Granzyme B ELISA Kit

for serum, plasma and cell culture supernatant

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
41116158
Nomenclature NACRES :
NA.32

Espèces réactives

mouse

Conditionnement

kit of 96 wells (12 strips x 8 wells)

Technique(s)

ELISA: suitable
capture ELISA: suitable

Entrée

sample type plasma
sample type serum
sample type cell culture supernatant(s)

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 12 pg/mL
standard curve range: 14.34-3500 pg/mL

Méthode de détection

colorimetric

Conditions d'expédition

wet ice

Température de stockage

−20°C

Informations sur le gène

mouse ... Gzmb(14939)

Catégories apparentées

Description générale

The Mouse Granzyme B ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of mouse Granzyme B in serum, plasma, cell culture supernatants and urine.
The Mouse Granzyme B enzyme-linked immunosorbent assay (ELISA) kit is an in vitro assay for the quantitative measurement of mouse granzyme B in serum, plasma, cell culture supernatants and urine. Granzyme B binds to mannose-6-phosphate/insulin-like growth factor II receptor. This protein is implicated in fast DNA fragmentation, a key step towards apoptosis in cells. Granzyme B is involved in the cleaving of pro-caspase-3, which leads to the activation of caspase-3. This protein also cleaves caspase-6, -7, -8, -9, and -10.

Immunogène

Recombinant Mouse Granzyme B

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Autres remarques

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Composants de kit également disponibles séparément

Réf. du produit
Description
FDS
  • RABELADAELISA 1X Assay/Sample Diluent Buffer A (Item D1)FDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)FDS
  • RABSTOP3ELISA Stop Solution (Item I)FDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)FDS
  • RABWASH420X Wash Buffer (Item B)FDS

Pictogrammes

Corrosion
GHS05

Mention d'avertissement

Warning

Mentions de danger

H290

Conseils de prudence

P234 - P390

Classification des risques

Met. Corr. 1

Code de la classe de stockage

8A - Combustible corrosive hazardous materials

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Brendan Bulik-Sullivan et al.
Nature biotechnology (2018-12-18)
Neoantigens, which are expressed on tumor cells, are one of the main targets of an effective antitumor T-cell response. Cancer immunotherapies to target neoantigens are of growing interest and are in early human trials, but methods to identify neoantigens either
Di Yang et al.
Scientific reports, 7(1), 1288-1288 (2017-04-30)
Systemic lupus erythematosus (SLE) features a decreased pool of CD4
Ciputra Adijaya Hartana et al.
PloS one, 13(7), e0200079-e0200079 (2018-07-03)
The immune system plays a significant role in urothelial bladder cancer (UBC) progression, with CD8+ T cells being capable to directly kill tumor cells using perforin and granzymes. However, tumors avoid immune recognition by escape mechanisms. In this study, we
Kosei Hasegawa et al.
Journal of immunotherapy (Hagerstown, Md. : 1997), 41(4), 201-207 (2018-02-13)
Cancer immunotherapy has now been established as a leading standard therapeutic option in a subset of patients with cancer. In this study, we conducted a phase I dose-escalation trial using a mixture of 5 peptides to vaccinate cervical cancer patients
Hannah Jonescheit et al.
Cells, 9(5) (2020-05-10)
Pancreatic ductal adenocarcinoma (PDAC) is a malignant gastrointestinal disease. The enzyme indoleamine-2,3-dioxgenase (IDO) is often overexpressed in PDAC and its downstream metabolite kynurenine has been reported to inhibit T cell activation and proliferation. Since γδ T cells are of high
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique